Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer

被引：0

作者：

Templeton, Arnoud J. ^{[1
,2
,3
]}

Omlin, Aurelius ^{[4
,5
]}

Berthold, Dominik ^{[6
]}

Beyer, Joerg ^{[7
]}

Burger, Irene A. ^{[8
]}

Eberli, Daniel ^{[9
]}

Engeleri, Daniel ^{[10
]}

Fankhauser, Christian ^{[11
]}

Fischer, Stefanie ^{[12
]}

Gillessen, Silke ^{[13
]}

Nicolas, Guillaume ^{[14
]}

Kroeze, Stephanie ^{[15
]}

Lorch, Anja ^{[16
]}

Muentener, Michael ^{[17
]}

Papachristofilou, Alexandros ^{[18
]}

Schaefer, Niklaus ^{[19
]}

Seiler, Daniel ^{[20
]}

Stenner, Frank ^{[21
]}

Tsantoulis, Petros ^{[22
]}

Vlajnic, Tatjana ^{[23
,24
]}

Zilli, Thomas ^{[25
]}

Zwahlen, Daniel ^{[26
]}

Cathomas, Richard ^{[27
]}

机构：

[1] St Clara Hosp, Med Oncol, Basel, Switzerland

[2] St Clara Res Ltd, Basel, Switzerland

[3] Univ Basel, Fac Med, Basel, Switzerland

[4] Univ Zurich, Onkozentrum Zurich, Zurich, Switzerland

[5] Tumorzentrum Hirslanden Zurich, Zurich, Switzerland

[6] CHUV Lausanne, Med Oncol, Vaud, Switzerland

[7] Inselspital Bern, Med Oncol, Univ Spital, Bern, Switzerland

[8] Kantonsspital Baden, Dept Nucl Med, Baden, Switzerland

[9] Univ Spital Zurich, Dept Urol, Zurich, Switzerland

[10] Kantonsspital St Gallen, Dept Urol, St Gallen, Switzerland

[11] Luzerner Kantonsspital, Dept Urol, Luzern, Switzerland

[12] Kantonsspital St Gallen, Dept Med Oncol & Hematol, St Gallen, Switzerland

[13] Ente Osped Cantonale EOC, Med Oncol, Bellinzona, Switzerland

[14] Univ Spital Basel, Dept Nucl Med, Basel, Switzerland

[15] Kantonsspital Aarau, Dept Radiooncol, Aarau, Switzerland

[16] Univ Spital Zurich, Med Oncol & Hematol, Zurich, Switzerland

[17] Stadtspital Zurich Triemli, Dept Urol, Zurich, Switzerland

[18] Univ Spital Basel, Dept Radiooncol, Basel, Switzerland

[19] CHU Vaudois, Dept Visceral Surg, Lausanne, Vaud, Switzerland

[20] Rotes Schloss Zurich, Dept Urol, Zurich, Switzerland

[21] Univ Spital Basel, Med Oncol & Hematol, Basel, Switzerland

[22] Univ Geneve HUG, Med Oncol & Hematol, Geneva, Switzerland

[23] Kantonsspital Graubunden, Inst Pathol, Chur, Switzerland

[24] Univ Spital Basel, Inst Med Genet & Pathol, Basel, Switzerland

[25] Ente Osped Cantonale EOC, Dept Radiooncol, Bellinzona, Switzerland

[26] Kantonsspital Winterthur, Dept Radiooncol, Winterthur, Switzerland

[27] Kantonsspital Graubunden, Div Hematol Oncol, Chur, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2023年 / 153卷

关键词：

THERAPY;

D O I：

10.57187/smw.2023.40108

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably in recent years. From clinical and health-economic perspectives, a rational and optimal use of the available options is of the utmost importance. While international guidelines list relevant pivotal trials and give recommendations for a variety of clinical scenarios, there is much room for interpretation, and several important questions remain highly debated. The goal of developing a national consensus on the use of these novel diagnostic and therapeutic strategies in order to improve disease management and eventually patient outcomes has prompted a Swiss consensus meeting. Experts from several specialties, including urology, medical oncology, radiation oncology, pathology and nuclear medicine, discussed and voted on questions of the current most important areas of uncertainty, including the staging and treatment of high-risk localized disease, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and use of new options to treat metastatic castration-resistant prostate cancer (mCRPC).

引用

页数：9

共 25 条

[1] A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE) [J].

Anttinen, Mikael ;

Ettala, Otto ;

Malaspina, Simona ;

Jambor, Ivan ;

Sandell, Minna ;

Kajander, Sami ;

Rinta-Kiikka, Irina ;

Schildt, Jukka ;

Saukko, Ekaterina ;

Rautio, Pentti ;

Timonen, Kirsi L. ;

Matikainen, Tuomas ;

Noponen, Tommi ;

Saunavaara, Jani ;

Loyttyniemi, Eliisa ;

Taimen, Pekka ;

Kemppainen, Jukka ;

Dean, Peter B. ;

Sequeiros, Roberto Blanco ;

Aronen, Hannu J. ;

Seppanen, Marko ;

Bostrom, Peter J. .

EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04) :635-644

[2] Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [J].

Attard, Gerhardt ;

Murphy, Laura ;

Clarke, Noel W. ;

Cross, William ;

Jones, Robert J. ;

Parker, Christopher C. ;

Gillessen, Silke ;

Cook, Adrian ;

Brawley, Chris ;

Amos, Claire L. ;

Atako, Nafisah ;

Pugh, Cheryl ;

Buckner, Michelle ;

Chowdhury, Simon ;

Malik, Zafar ;

Russell, J. Martin ;

Gilson, Clare ;

Rush, Hannah ;

Bowen, Jo ;

Lydon, Anna ;

Pedley, Ian ;

O'Sullivan, Joe M. ;

Birtle, Alison ;

Gale, Joanna ;

Srihari, Narayanan ;

Thomas, Carys ;

Tanguay, Jacob ;

Wagstaff, John ;

Das, Prantik ;

Gray, Emma ;

Alzoueb, Mymoona ;

Parikh, Omi ;

Robinson, Angus ;

Syndikus, Isabel ;

Wylie, James ;

Zarkar, Anjali ;

Thalmann, George ;

de Bono, Johann S. ;

Dearnaley, David P. ;

Mason, Malcolm D. ;

Gilbert, Duncan ;

Langley, Ruth E. ;

Millman, Robin ;

Matheson, David ;

Sydes, Matthew R. ;

Brown, Louise C. ;

Parmar, Mahesh K. B. ;

James, Nicholas D. .

LANCET, 2022, 399 (10323) :447-460

[3] Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment [J].

Attard, Gerhardt ;

Borre, Michael ;

Gurney, Howard ;

Loriot, Yohann ;

Andresen-Daniil, Corina ;

Kalleda, Ranjith ;

Trinh Pham ;

Taplin, Mary-Ellen .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) :2639-+

[4]

Chi KN, JOURNALASCO GU

[5]

Clarke Noel W, 2022, NEJM Evid, V1, pEVIDoa2200043, DOI 10.1056/EVIDoa2200043

[6] EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer [J].

Cornford, Philip ;

van den Bergh, Roderick C. N. ;

Briers, Erik ;

Van den Broeck, Thomas ;

Cumberbatch, Marcus G. ;

De Santis, Maria ;

Fanti, Stefano ;

Fossati, Nicola ;

Gandaglia, Giorgio ;

Gillessen, Silke ;

Grivas, Nikolaos ;

Grummet, Jeremy ;

Henry, Ann M. ;

van der Kwast, Theodorus H. ;

Lam, Thomas B. ;

Lardas, Michael ;

Liew, Matthew ;

Mason, Malcolm D. ;

Moris, Lisa ;

Oprea-Lager, Daniela E. ;

van der Poel, Henk G. ;

Rouviere, Olivier ;

Schoots, Ivo G. ;

Tilki, Derya ;

Wiegel, Thomas ;

Willemse, Peter-Paul M. ;

Mottet, Nicolas .

EUROPEAN UROLOGY, 2021, 79 (02) :263-282

[7] Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, J. ;

Mateo, J. ;

Fizazi, K. ;

Saad, F. ;

Shore, N. ;

Sandhu, S. ;

Chi, K. N. ;

Sartor, O. ;

Agarwal, N. ;

Olmos, D. ;

Thiery-Vuillemin, A. ;

Twardowski, P. ;

Mehra, N. ;

Goessl, C. ;

Kang, J. ;

Burgents, J. ;

Wu, W. ;

Kohlmann, A. ;

Adelman, C. A. ;

Hussain, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102

[8] Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe [J].

de Bono, Johann S. ;

Chowdhury, Simon ;

Feyerabend, Susan ;

Elliott, Tony ;

Grande, Enrique ;

Melhem-Bertrandt, Amal ;

Baron, Benoit ;

Hirmand, Mohammad ;

Werbrouck, Patrick ;

Fizazi, Karim .

EUROPEAN UROLOGY, 2018, 74 (01) :37-45

[9] Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design [J].

Fizazi, Karim ;

Foulon, Stephanie ;

Carles, Joan ;

Roubaud, Guilhem ;

McDermott, Ray ;

Flechon, Aude ;

Tombal, Bertrand ;

Supiot, Stephane ;

Berthold, Dominik ;

Ronchin, Philippe ;

Kacso, Gabriel ;

Gravis, Gwenaelle ;

Calabro, Fabio ;

Berdah, Jean-Francois ;

Hasbini, Ali ;

Silva, Marlon ;

Thiery-Vuillemin, Antoine ;

Latorzeff, Igor ;

Mourey, Loic ;

Laguerre, Brigitte ;

Abadie-Lacourtoisie, Sophie ;

Martin, Etienne ;

El Kouri, Claude ;

Escande, Anne ;

Rosello, Alvar ;

Magne, Nicolas ;

Schlurmann, Friederike ;

Priou, Frank ;

Chand-Fouche, Marie-Eve ;

Freixa, Salvador Villa ;

Jamaluddin, Muhammad ;

Rieger, Isabelle ;

Bossi, Alberto .

LANCET, 2022, 399 (10336) :1695-1707

[10] Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) [J].

Francini, Edoardo ;

Gray, Kathryn P. ;

Xie, Wanling ;

Shaw, Grace K. ;

Valenca, Loana ;

Bernard, Brandon ;

Albiges, Laurence ;

Harshman, Lauren C. ;

Kantoff, Philip W. ;

Taplin, Mary-Ellen ;

Sweeney, Cristopher J. .

PROSTATE, 2018, 78 (12) :889-895

← 1 2 3 →